Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine-Supplemented Articaine for AV Fistula Creation
NCT04171349Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dexmedetomidine in chronic kidney disease (CKD) (2 arms), sponsored by Ain Shams University. Primary endpoints: Duration of sensory block at 24 hours and Duration of motor block at 24 hours. Started Jun 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04171349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171349.